Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Virology Journal
Published in: Virology Journal 1/2011

Open Access 01-12-2011 | Short report

Human-Phosphate-Binding-Protein inhibits HIV-1 gene transcription and replication

Authors: Thomas Cherrier, Mikael Elias, Alicia Jeudy, Guillaume Gotthard, Valentin Le Douce, Houda Hallay, Patrick Masson, Andrea Janossy, Ermanno Candolfi, Olivier Rohr, Eric Chabrière, Christian Schwartz

Published in: Virology Journal | Issue 1/2011

Login to get access

Abstract

The Human Phosphate-Binding protein (HPBP) is a serendipitously discovered lipoprotein that binds phosphate with high affinity. HPBP belongs to the DING protein family, involved in various biological processes like cell cycle regulation. We report that HPBP inhibits HIV-1 gene transcription and replication in T cell line, primary peripherical blood lymphocytes and primary macrophages. We show that HPBP is efficient in naïve and HIV-1 AZT-resistant strains. Our results revealed HPBP as a new and potent anti HIV molecule that inhibits transcription of the virus, which has not yet been targeted by HAART and therefore opens new strategies in the treatment of HIV infection.
Appendix
Available only for authorised users
Literature
1.
Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C, et al.: Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983, 220: 868-871. 10.1126/science.6189183CrossRefPubMed
2.
Geeraert L, Kraus G, Pomerantz RJ: Hide-and-seek: the challenge of viral persistence in HIV-1 infection. Annu Rev Med 2008, 59: 487-501. 10.1146/annurev.med.59.062806.123001CrossRefPubMed
3.
Hermankova M, Ray SC, Ruff C, Powell-Davis M, Ingersoll R, D'Aquila RT, Quinn TC, Siliciano JD, Siliciano RF, Persaud D: HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy. Jama 2001, 286: 196-207. 10.1001/jama.286.2.196CrossRefPubMed
4.
Kieffer TL, Finucane MM, Nettles RE, Quinn TC, Broman KW, Ray SC, Persaud D, Siliciano RF: Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis 2004, 189: 1452-1465. 10.1086/382488CrossRefPubMed
5.
Nettles RE, Kieffer TL, Kwon P, Monie D, Han Y, Parsons T, Cofrancesco J Jr, Gallant JE, Quinn TC, Jackson B, et al.: Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. Jama 2005, 293: 817-829. 10.1001/jama.293.7.817CrossRefPubMed
6.
7.
Redel L, Le Douce V, Cherrier T, Marban C, Janossy A, Aunis D, Van Lint C, Rohr O, Schwartz C: HIV-1 regulation of latency in the monocyte-macrophage lineage and in CD4+ T lymphocytes. J Leukoc Biol 2009.
8.
9.
Aquaro S, Calio R, Balzarini J, Bellocchi MC, Garaci E, Perno CF: Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir. Antiviral Res 2002, 55: 209-225. 10.1016/S0166-3542(02)00052-9CrossRefPubMed
10.
Perno CF, Newcomb FM, Davis DA, Aquaro S, Humphrey RW, Calio R, Yarchoan R: Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus. J Infect Dis 1998, 178: 413-422.CrossRefPubMed
11.
Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, Hermankova M, Chadwick K, Margolick J, Quinn TC, et al.: Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997, 387: 183-188. 10.1038/387183a0CrossRefPubMed
12.
Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, et al.: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278: 1295-1300. 10.1126/science.278.5341.1295CrossRefPubMed
13.
Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S, Talal A, Racz P, Perelson AS, Korber BT, et al.: Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999, 340: 1605-1613. 10.1056/NEJM199905273402101CrossRefPubMed
14.
McGee B, Smith N, Aweeka F: HIV pharmacology: barriers to the eradication of HIV from the CNS. HIV Clin Trials 2006, 7: 142-153. 10.1310/AW2H-TP5C-NP43-K6BYCrossRefPubMed
15.
Sawchuk RJ, Yang Z: Investigation of distribution, transport and uptake of anti-HIV drugs to the central nervous system. Adv Drug Deliv Rev 1999, 39: 5-31. 10.1016/S0169-409X(99)00017-4CrossRefPubMed
16.
Solas C, Lafeuillade A, Halfon P, Chadapaud S, Hittinger G, Lacarelle B: Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003, 47: 238-243. 10.1128/AAC.47.1.238-243.2003PubMedCentralCrossRefPubMed
17.
18.
Taiwo B, Murphy RL, Katlama C: Novel antiretroviral combinations in treatmentexperienced patients with HIV infection: rationale and results. Drugs 70: 1629-1642.
19.
Baba M: Recent status of HIV-1 gene expression inhibitors. Antiviral Res 2006, 71: 301-306. 10.1016/j.antiviral.2006.01.002CrossRefPubMed
20.
21.
Stevens M, De Clercq E, Balzarini J: The regulation of HIV-1 transcription: molecular targets for chemotherapeutic intervention. Med Res Rev 2006, 26: 595-625. 10.1002/med.20081CrossRefPubMed
22.
Baba M: Cellular factors as alternative targets for inhibition of HIV-1. Antiviral Res 1997, 33: 141-152. 10.1016/S0166-3542(96)01010-8CrossRefPubMed
23.
24.
Daelemans D, Vandamme AM, De Clercq E: Human immunodeficiency virus gene regulation as a target for antiviral chemotherapy. Antivir Chem Chemother 1999, 10: 1-14.CrossRefPubMed
25.
Darbinian-Sarkissian N, Darbinyan A, Otte J, Radhakrishnan S, Sawaya BE, Arzumanyan A, Chipitsyna G, Popov Y, Rappaport J, Amini S, Khalili K: p27(SJ), a novel protein in St John's Wort, that suppresses expression of HIV-1 genome. Gene Ther 2006, 13: 288-295. 10.1038/sj.gt.3302649CrossRefPubMed
26.
Lesner A, Shilpi R, Ivanova A, Gawinowicz MA, Lesniak J, Nikolov D, Simm M: Identification of X-DING-CD4, a new member of human DING protein family that is secreted by HIV-1 resistant CD4(+) T cells and has anti-viral activity. Biochem Biophys Res Commun 2009, 389: 284-289. 10.1016/j.bbrc.2009.08.140PubMedCentralCrossRefPubMed
27.
Berna A, Bernier F, Chabriere E, Elias M, Scott K, Suh A: For whom the bell tolls? DING proteins in health and disease. Cell Mol Life Sci 2009, 66: 2205-2218. 10.1007/s00018-009-0006-6CrossRefPubMed
28.
Elias M, Liebschner D, Gotthard G, Chabriere E: Structural insights and ab initio sequencing within the DING proteins family. J Synchrotron Radiat 2011, 18: 45-49.PubMedCentralCrossRefPubMed
29.
Berna A, Bernier F, Chabriere E, Perera T, Scott K: DING proteins; novel members of a prokaryotic phosphate-binding protein superfamily which extends into the eukaryotic kingdom. Int J Biochem Cell Biol 2008, 40: 170-175. 10.1016/j.biocel.2007.02.004CrossRefPubMed
30.
Collombet JM, Elias M, Gotthard G, Four E, Renault F, Joffre A, Baubichon D, Rochu D, Chabriere E: Eukaryotic DING proteins are endogenous: an immunohistological study in mouse tissues. PLoS One 2010, 5: e9099.PubMedCentralCrossRefPubMed
31.
Contreras-Martel C, Carpentier P, Morales R, Renault F, Chesne-Seck ML, Rochu D, Masson P, Fontecilla-Camps JC, Chabriere E: Crystallization and preliminary X-ray diffraction analysis of human phosphate-binding protein. Acta Crystallogr Sect F Struct Biol Cryst Commun 2006, 62: 67-69.PubMedCentralCrossRefPubMed
32.
Morales R, Berna A, Carpentier P, Contreras-Martel C, Renault F, Nicodeme M, Chesne-Seck ML, Bernier F, Dupuy J, Schaeffer C, et al.: Serendipitous discovery and X-ray structure of a human phosphate binding apolipoprotein. Structure 2006, 14: 601-609. 10.1016/j.str.2005.12.012CrossRefPubMed
33.
Renault F, Chabriere E, Andrieu JP, Dublet B, Masson P, Rochu D: Tandem purification of two HDL-associated partner proteins in human plasma, paraoxonase (PON1) and phosphate binding protein (HPBP) using hydroxyapatite chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2006, 836: 15-21. 10.1016/j.jchromb.2006.03.029CrossRefPubMed
34.
Fokine A, Morales R, Contreras-Martel C, Carpentier P, Renault F, Rochu D, Chabriere E: Direct phasing at low resolution of a protein copurified with human paraoxonase (PON1). Acta Crystallogr D Biol Crystallogr 2003, 59: 2083-2087. 10.1107/S0907444903017682CrossRefPubMed
35.
Liebschner D, Elias M, Moniot S, Fournier B, Scott K, Jelsch C, Guillot B, Lecomte C, Chabriere E: Elucidation of the phosphate binding mode of DING proteins revealed by subangstrom Xray crystallography. J Am Chem Soc 2009, 131: 7879-7886. 10.1021/ja901900yCrossRefPubMed
36.
Morales R, Berna A, Carpentier P, Contreras-Martel C, Renault F, Nicodeme M, Chesne-Seck ML, Bernier F, Dupuy J, Schaeffer C, et al.: [Discovery and crystallographic structure of human apolipoprotein]. Ann Pharm Fr 2007, 65: 98-107.CrossRefPubMed
37.
38.
Diemer H, Elias M, Renault F, Rochu D, Contreras-Martel C, Schaeffer C, Van Dorsselaer A, Chabriere E: Tandem use of X-ray crystallography and mass spectrometry to obtain ab initio the complete and exact amino acids sequence of HPBP, a human 38-kDa apolipoprotein. Proteins 2008, 71: 1708-1720.CrossRefPubMed
39.
Gan ZR, Lewis SD, Stone JR, Shafer JA: Reconstitution of catalytically competent human zeta-thrombin by combination of zeta-thrombin residues A1-36 and B1-148 and an Escherichia coli expressed polypeptide corresponding to zeta-thrombin residues B149-259. Biochemistry 1991, 30: 11694-11699. 10.1021/bi00114a013CrossRefPubMed
40.
Leone C, Le Pavec G, Meme W, Porcheray F, Samah B, Dormont D, Gras G: Characterization of human monocyte-derived microglia-like cells. Glia 2006, 54: 183-192. 10.1002/glia.20372CrossRefPubMed
41.
Rohr O, Lecestre D, Chasserot-Golaz S, Marban C, Avram D, Aunis D, Leid M, Schaeffer E: Recruitment of Tat to heterochromatin protein HP1 via interaction with CTIP2 inhibits human immunodeficiency virus type 1 replication in microglial cells. J Virol 2003, 77: 5415-5427. 10.1128/JVI.77.9.5415-5427.2003PubMedCentralCrossRefPubMed
42.
Herbein G, Mahlknecht U, Batliwalla F, Gregersen P, Pappas T, Butler J, O'Brien WA, Verdin E: Apoptosis of CD8+ T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4. Nature 1998, 395: 189-194. 10.1038/26026CrossRefPubMed
43.
Larder BA, Darby G, Richman DD: HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989, 243: 1731-1734. 10.1126/science.2467383CrossRefPubMed
44.
Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65: 55-63. 10.1016/0022-1759(83)90303-4CrossRefPubMed
45.
Darbinian N, Czernik M, Darbinyan A, Elias M, Chabriere E, Bonasu S, Khalili K, Amini S: Evidence for phosphatase activity of p27SJ and its impact on the cell cycle. J Cell Biochem 2009, 107: 400-407. 10.1002/jcb.22135PubMedCentralCrossRefPubMed
46.
Darbinian N, Gomberg R, Mullen L, Garcia S, White MK, Khalili K, Amini S: Suppression of HIV-1 transcriptional elongation by a DING phosphatase. J Cell Biochem 2011, 112: 225-232.PubMedCentralCrossRefPubMed
47.
Mukerjee R, Deshmane SL, Darbinian N, Czernik M, Khalili K, Amini S, Sawaya BE: St. John's Wort protein, p27SJ, regulates the MCP-1 promoter. Mol Immunol 2008, 45: 4028-4035. 10.1016/j.molimm.2008.06.001PubMedCentralCrossRefPubMed
48.
Cihlar T, Birkus G, Greenwalt DE, Hitchcock MJ: Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors. Antiviral Res 2002, 54: 37-45. 10.1016/S0166-3542(01)00210-8CrossRefPubMed
49.
Hazen R, Lanier ER: Relative anti-HIV-1 efficacy of lamivudine and emtricitabine in vitro is dependent on cell type. J Acquir Immune Defic Syndr 2003, 32: 255-258. 10.1097/00126334-200303010-00003CrossRefPubMed
50.
Garcia JA, Harrich D, Soultanakis E, Wu F, Mitsuyasu R, Gaynor RB: Human immunodeficiency virus type 1 LTR TATA and TAR region sequences required for transcriptional regulation. Embo J 1989, 8: 765-778.PubMedCentralPubMed
51.
Kingsman SM, Kingsman AJ: The regulation of human immunodeficiency virus type-1 gene expression. Eur J Biochem 1996, 240: 491-507. 10.1111/j.1432-1033.1996.0491h.xCrossRefPubMed
52.
Pereira LA, Bentley K, Peeters A, Churchill MJ, Deacon NJ: A compilation of cellular transcription factor interactions with the HIV-1 LTR promoter. Nucleic Acids Res 2000, 28: 663-668. 10.1093/nar/28.3.663PubMedCentralCrossRefPubMed
53.
Rohr O, Marban C, Aunis D, Schaeffer E: Regulation of HIV-1 gene transcription: from lymphocytes to microglial cells. J Leukoc Biol 2003, 74: 736-749. 10.1189/jlb.0403180CrossRefPubMed
54.
Deeks SG: Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet 2003, 362: 2002-2011. 10.1016/S0140-6736(03)15022-2CrossRefPubMed
55.
56.
Rochu D, Chabriere E, Renault F, Elias M, Clery-Barraud C, Masson P: Stabilization of the active form(s) of human paraoxonase by human phosphate-binding protein. Biochem Soc Trans 2007, 35: 1616-1620. 10.1042/BST0351616CrossRefPubMed
57.
Parra S, Alonso-Villaverde C, Coll B, Ferre N, Marsillach J, Aragones G, Mackness M, Mackness B, Masana L, Joven J, Camps J: Serum paraoxonase-1 activity and concentration are influenced by human immunodeficiency virus infection. Atherosclerosis 2007, 194: 175-181. 10.1016/j.atherosclerosis.2006.07.024CrossRefPubMed
58.
Parra S, Marsillach J, Aragones G, Beltran R, Montero M, Coll B, Mackness B, Mackness M, Alonso-Villaverde C, Joven J, Camps J: Paraoxonase-1 gene haplotypes are associated with metabolic disturbances, atherosclerosis, and immunologic outcome in HIV-infected patients. J Infect Dis 2010, 201: 627-634.CrossRefPubMed
Metadata
Title
Human-Phosphate-Binding-Protein inhibits HIV-1 gene transcription and replication
Authors
Thomas Cherrier
Mikael Elias
Alicia Jeudy
Guillaume Gotthard
Valentin Le Douce
Houda Hallay
Patrick Masson
Andrea Janossy
Ermanno Candolfi
Olivier Rohr
Eric Chabrière
Christian Schwartz
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2011
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-8-352

Other articles of this Issue 1/2011

Virology Journal 1/2011 Go to the issue

Research

Revised cutoff values of ALT and HBV DNA level can better differentiate HBeAg (-) chronic inactive HBV patients from active carriers

Research

Identification of critical residues of influenza neuraminidase in viral particle release

Short report

Lack of Processing of the Expressed ORF1 Gene Product of Hepatitis E Virus

Research

Establishment of persistent infection with foot-and-mouth disease virus in BHK-21 cells

Research

Absence of vaccine-enhanced RSV disease and changes in pulmonary dendritic cells with adenovirus-based RSV vaccine

Research

Expression and characterization of recombinant VP19c protein and N-terminal from duck enteritis virus
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits